Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
May 10, 2021 07:30 ET
|
Voyager Therapeutics, Inc.
- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference,...
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
April 28, 2021 08:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
April 26, 2021 08:00 ET
|
Voyager Therapeutics, Inc.
One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass., April 26, 2021 ...
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
February 25, 2021 16:01 ET
|
Voyager Therapeutics, Inc.
Expects to Provide Complete Response to FDA Requests on IND Application for VY-HTT01 for Huntington’s Disease in the First Half of 2021Continues to Progress Pipeline and Platform Activities with...
Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
February 18, 2021 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
February 02, 2021 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 11, 2021 16:03 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
December 22, 2020 16:17 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences...
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
November 09, 2020 16:00 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates. ...
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
October 12, 2020 16:01 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...